Clinical Trials Browser

INDUSTRY × Interventional × imetelstat × Clear all

NCT05583552 2026-05-12

IMpress

Phase 2 Active not recruiting

46 enrolled 21 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2/3 Active not recruiting

289 enrolled 35 charts 1 FDA

Myelodysplastic Syndromes, Recurrence

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Phase 3 Active not recruiting

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Phase 2 Completed

80 enrolled 31 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01242930 2016-05-12

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01137968 2016-01-26

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01243073 2016-01-26

ET/PV

Phase 2 Completed

Polycythemia Vera, Thrombocythemia, Essential

NCT01256762 2016-01-26

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00310895 2015-12-24

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Phase 1 Completed

Recurrence

NCT00510445 2015-12-24

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00594126 2015-12-24

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00718601 2015-12-24

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell